NCT04913337

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

• Status: Active Not Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 179 (estimated)
• Sponsor: NGM Biopharmaceuticals, Inc · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Conditions

• Mesothelioma
• Glioblastoma
• Renal Cell Carcinoma
• Non Small Cell Lung Cancer
• Melanoma
• Pancreatic Ductal Adenocarcinoma
• Gastric Cancer
• Squamous Cell Carcinoma of Head and Neck
• Cholangiocarcinoma
• Breast Cancer
• Ovarian Cancer
• Cervical Cancer
• Endocervical Cancer
• Colorectal Cancer
• Esophageal Cancer

Interventions

Type	Name	Description
DRUG	NGM707	Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
DRUG	NGM707 plus pembrolizumab (KEYTRUDA®)	Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
DRUG	NGM707 plus pembrolizumab (KEYTRUDA®)	Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
DRUG	NGM707 plus pembrolizumab (KEYTRUDA®)	Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
DRUG	NGM707 plus pembrolizumab (KEYTRUDA®)	Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated. Drug: pembrolizumab (KEYTRUDA®) Pembrolizumab (KEYTRUDA®) will be administered intravenously (IV) every 3 weeks in a 21 day cycle.
DRUG	NGM707	Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
DRUG	NGM707	Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
DRUG	NGM707	Drug: NGM707 NGM707 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.

Timeline

• Start date: 2021-06-09
• Primary completion: 2025-02-01
• Completion: 2025-07-01
• First posted: 2021-06-04
• Last updated: 2024-10-02

Locations

27 sites across 3 countries: United States, South Korea, Taiwan

Regulatory

• FDA-regulated drug study